Cargando…
A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated int...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425342/ https://www.ncbi.nlm.nih.gov/pubmed/25636188 http://dx.doi.org/10.1016/j.bjid.2014.10.010 |
_version_ | 1784778427106066432 |
---|---|
author | Qu, Xiao-Yu Hu, Ting-Ting Zhou, Wei |
author_facet | Qu, Xiao-Yu Hu, Ting-Ting Zhou, Wei |
author_sort | Qu, Xiao-Yu |
collection | PubMed |
description | OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. RESULTS: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. CONCLUSION: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment. |
format | Online Article Text |
id | pubmed-9425342 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-94253422022-08-31 A meta-analysis of efficacy and safety of doripenem for treating bacterial infections Qu, Xiao-Yu Hu, Ting-Ting Zhou, Wei Braz J Infect Dis Original Article OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. RESULTS: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. CONCLUSION: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment. Elsevier 2015-01-27 /pmc/articles/PMC9425342/ /pubmed/25636188 http://dx.doi.org/10.1016/j.bjid.2014.10.010 Text en © 2015 Elsevier Editora Ltda. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Qu, Xiao-Yu Hu, Ting-Ting Zhou, Wei A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title_full | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title_fullStr | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title_full_unstemmed | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title_short | A meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
title_sort | meta-analysis of efficacy and safety of doripenem for treating bacterial infections |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425342/ https://www.ncbi.nlm.nih.gov/pubmed/25636188 http://dx.doi.org/10.1016/j.bjid.2014.10.010 |
work_keys_str_mv | AT quxiaoyu ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT hutingting ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT zhouwei ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT quxiaoyu metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT hutingting metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections AT zhouwei metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections |